ortho·cell
advancing tissue repair & regeneration

Orthocell secures CelGro® patent protection in Japan

- **Japan divisional patent granted** for CelGro® soft tissue reconstruction platform
- Patent covers the **method of combining cells and scaffolds** as an aid in the surgical repair of soft tissue injuries
- CelGro® patents now **granted in the US, China, Canada, Singapore, Australia and New Zealand**
- CelGro® is approved for use in Europe and **gathering significant market traction**

Perth, Australia; 23rd October 2018: Regenerative medicine company Orthocell Limited has today announced it has been granted a Japanese patent for its CelGro® collagen medical device platform for soft tissue regeneration and repair applications. The patent entitled **"A Medical Procedure Kit and A Related Method"** provides additional important intellectual property to protect the CelGro® product platform and expires on 5 June 2037.

Orthocell Managing Director Paul Anderson said: "Orthocell is focused on building and maintaining patent protection for our technologies and treatment processes. Securing this patent for soft tissue repair in Japan is another milestone in strengthening our IP position in key global markets and compliments the progression of our products through the registration processes in key markets."

CelGro® is manufactured by Orthocell at its quality controlled (GMP) facility, using proprietary SMRT™ tissue engineering process, developed in conjunction with Professor Minghao Zheng and the University of Western Australia. CelGro® is a customisable collagen medical device with numerous competitive advantages over existing synthetic and biologic tissue repair devices, particularly in the areas of cell compatibility, tensile strength and the promotion of quality tissue in growth and repair.

CelGro® has been shown to improve tissue in-growth and repair in clinical studies using the collagen medical device to guide bone regeneration within the jaw and currently being assessed for performance in the rotator cuff tendon within the shoulder, to assist in the rejoining of severed, or damaged peripheral nerves and repair of articular cartilage in the hip.

The Company believes CelGro® represents a breakthrough in soft tissue reconstruction and offers significant commercial potential in its existing addressable markets of bone, tendon, nerve and cartilage as well as much wider applications in general surgical and soft tissue reconstructive applications. The global addressable market for CelGro® is in excess of US2.6bn and growing.

Orthocell has a clear marketing strategy in place and is well positioned to drive product adoption and sales of CelGro® in the important and growing EU market, following the recent appointments to the Medical Scientific Advisory Board, engagement of first distributors, achievement of first product use and sales in the EU market.

For more information, please contact:

General enquiries	Investor enquiries	Media enquiries
Paul Anderson	**Joel Seah**	**Haley Chartres**
Orthocell Limited	**Vesparum Capital**	**Hales^2 Communications**
Managing Director		
P: +61 8 9360 2888	P: +61 3 8582 4800	P: +61 423 139 163
E: paulanderson@orthocell.com.au	E: orthocell@vesparum.com	E: haley@h-squared.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell's portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. Orthocell recently received European regulatory approval (CE Mark) for CelGro®. The collagen medical device can now be marketed and sold within the European Union for a range of dental bone and soft tissue regeneration procedures and is being readied for first approval in the US.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter **@Orthocellltd** and Linkedin www.linkedin.com/company/orthocell-ltd